Marker Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Marker Therapeutics, Inc. (MRKR) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-10.73-8.24-29.93-41.88-28.71-21.43
Depreciation & Amortization0.000.003.683.161.080.29
Stock Based Compensation0.250.863.305.965.230.00
Change in Working Capital-0.422.85-4.765.472.54-2.31
Change in Accounts Receivable-1.321.37-2.401.000.060.00
Change in Accounts Payable0.39-0.72-1.324.143.050.00
Change in Other Working Capital0.892.190.10-0.82-0.700.00
Other Operating Activities0.00-5.81-0.285.585.065.17
Net Cash from Operating Activities-10.91-16.44-26.97-27.28-20.03-18.28
Investing Activities
Capital Expenditures0.000.00-4.95-3.136.790.37
Sales/Maturities of Investments0.000.00-4.95-3.13-9.25-0.37
Other Investing Activities0.0018.66-4.95-3.13-9.25-0.37
Net Cash from Investing Activities0.0018.66-4.95-3.13-9.25-0.37
Financing Activities
Common Stock Issued14.931.110.2052.556.190.00
Other Financing Activities0.060.000.000.000.000.00
Net Cash from Financing Activities14.991.110.2052.566.740.82
Summary
Net Change in Cash4.083.33-31.7222.14-22.55-17.84
Cash at Beginning of Period15.1111.7843.5021.3543.9061.75
Cash at End of Period19.1915.1111.7843.5021.3543.90
Free Cash Flow-10.91-16.44-26.97-30.41-20.03-18.28